Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iradimed (IRMD) Shares Outstanding (Diluted Average) (2019 - 2026)

Iradimed has reported Shares Outstanding (Diluted Average) over the past 8 years, most recently at $12.9 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) changed 0.34% to $12.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $12.9 million through Mar 2026, changed 0.34% year-over-year, with the annual reading at $12.8 million for FY2024, 0.48% changed from the prior year.
  • Shares Outstanding (Diluted Average) was $12.9 million for Q1 2026 at Iradimed, roughly flat from $12.8 million in the prior quarter.
  • Over five years, Shares Outstanding (Diluted Average) peaked at $12.9 million in Q1 2026 and troughed at $12.6 million in Q2 2022.
  • The 5-year median for Shares Outstanding (Diluted Average) is $12.7 million (2023), against an average of $12.7 million.
  • Year-over-year, Shares Outstanding (Diluted Average) grew 0.78% in 2023 and then increased 0.21% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $12.6 million in 2022, then rose by 0.69% to $12.7 million in 2023, then grew by 0.48% to $12.8 million in 2024, then rose by 0.46% to $12.8 million in 2025, then rose by 0.22% to $12.9 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's Shares Outstanding (Diluted Average) are $12.9 million (Q1 2026), $12.8 million (Q3 2025), and $12.8 million (Q2 2025).